The SGLT2:SGLT1 pharmacological selectivity ratio explained a considerable amount of heterogeneity in the risk of stroke (pseudo-R2 = 78%; p = 0.011) (Fig. 3A). This evidence concerns the gene SLC5A1 and stroke disorder.